Skip to search formSkip to main contentSkip to account menu

CALGB 9251 Regimen

A regimen comprised of a prephase (or cytoreductive phase), followed by two different chemotherapy regimens, given on an alternating schedule and… 
National Institutes of Health

Related topics

Related topics

12 relations
CyclophosphamideCytarabineDexamethasoneDoxorubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Breast cancer: Weekly paclitaxel—still preferred first-line taxane for mBC
Taxane-based regimens are among the preferred first-line chemotherapy options for metastatic breast cancer, with weekly… 
2011
2011
Intense dose-dense (idd) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (ETC) compared with conventionally scheduled chemotherapy in high-risk breast cancer…
1018 Background: Dose-dense chemotherapy has become one of the possible standards in breast cancer patients (pts). Both, CALGB… 
2009
2009
Discovery of a new phospho-HER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping.
11009 Background: Effective treatment of breast cancer through the targeting of the HER2 protein in human breast cancer… 
2009
2009
Influence of anthracycline- and taxane-based neoadjuvant chemotherapy on tumor HER2 protein expression in locally advanced breast cancers: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN…
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #703 Background: The I-SPY trial is a multi… 
Review
2006
Review
2006
Cancer and Leukemia Group B Clinical Research Associates Committee
The Cancer and Leukemia Group B is dedicated to developing and implementing training programs that will enhance the skills and… 
2005
2005
The addition of taxanes to adjuvant chemotherapy for lymph node positive (N+) early breast cancer (BC): Institutional practice variation in the National Comprehensive Cancer Network (NCCN)
654 Background: The addition of adjuvant (ADJ) paclitaxel to N+ BC has been evaluated in 2 large randomized studies. NSABP B28… 
Highly Cited
2004
Highly Cited
2004
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803)
3500 Background: Irinotecan prolongs survival in second line 5FU-refractory metastatic colorectal cancer (MCRC). First line… 
Highly Cited
2004
Highly Cited
2004
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803).
3500 Background: Irinotecan prolongs survival in second line 5FU-refractory metastatic colorectal cancer (MCRC). First line… 
2004
2004
A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials.
4506 Background: A prostate-specific antigen (PSA) decline of > 50% is associated with a prolongation in survival for patients… 
Review
2003
Review
2003
Commentary (Rai/Mehrotra): Current Status of Monoclonal Antibody Therapy for Chronic Lymphocytic Leukemia
Drs. Nabhan, Dyer, and Rosen provide an excellent and comprehensive review of the therapeutic role of rituximab (Rituxan) and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)